Amineptine

Amineptine
Clinical data
Trade names	Survector, others
Other names	S-1694
Routes of; administration	Oral
ATC code	N06AA19 (WHO) ;
Legal status
Legal status	AU: Unscheduled; BR: Class B1 (Psychoactive drugs); CA: Schedule III; DE: Anlage II (Authorized trade only, not prescriptible); UK: Class C; US: Schedule I; UN: Psychotropic Schedule II;
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	Amineptine: 0.8–1.0 hours; Metabolite: 1.5–2.5 hours
Excretion	Renal
Identifiers
	IUPAC name 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)amino]heptanoic acid;
CAS Number	57574-09-1 ;
PubChem CID	34870;
DrugBank	DB04836 ;
ChemSpider	32091 ;
UNII	27T1I13L6G;
KEGG	D07335 ;
ChEBI	CHEBI:32499 ;
ChEMBL	ChEMBL418995 ;
CompTox Dashboard (EPA)	DTXSID1048831 ;
ECHA InfoCard	100.055.271
Chemical and physical data
Formula	C22H28NO2
Molar mass	338.471 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)CCCCCCNC1c2ccccc2CCc2ccccc21;
	InChI InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25) ; Key:ONNOFKFOZAJDHT-UHFFFAOYSA-N ;
	(verify)

Amineptine, formerly sold under the brand name Survector among others, is an atypical antidepressant of the tricyclic antidepressant (TCA) family. It acts as a selective and mixed dopamine reuptake inhibitor and releasing agent, and to a lesser extent as a norepinephrine reuptake inhibitor.

Amineptine was developed by the French Society of Medical research in the 1960s. Introduced in France in 1978 by the pharmaceutical company Servier, amineptine soon gained a reputation for abuse due to its short-lived, but pleasant, stimulant effect experienced by some patients.

After widespread adoption of this drug, cases of hepatotoxicity emerged, some serious. This, along with the potential for abuse, led to the suspension of the French marketing authorization for Survector in 1999.

Amineptine is illegal in both Germany and the United States.